Psy Therapeutics

Novel non-opioid, non-addictive small molecule analgesic for subacute and chronic pain, with additional application in PTSD-related sleep disturbance. Undisclosed molecular target. Designed to provide effective pain relief without opioid misuse risk and enable transition from opioid to non-opioid treatment. US composition of matter patent allowed (protection through at least 2042); international patent applications pending. Preclinical efficacy demonstrated in neuropathic, inflammatory, and post-operative pain models.

Legacy/secondary PSY-05 record for anxiety/PTSD and possibly the same chemical estate now surfaced as PSY-05001. Psy Therapeutics used the PSY-05 name in March 2025 company highlights for an oral pain/PTSD programme entering IND-enabling, while the current company pipeline lists PSY-05001 as the pain/PTSD IND-enabling asset and does not show a separate PSY-05. Treat as a mapping-cleanup item until the company clarifies nomenclature.

Novel brain-penetrant COMT (catechol-O-methyltransferase) inhibitor based on non-nitrocatechol scaffold discovered via DNA-encoded library (DEL) screen with X-Chem (200B+ molecule library). Enhances dopamine signaling. Avoids toxicity and poor brain penetration of existing nitrocatechol-based COMT inhibitors (e.g., entacapone, tolcapone). Also being explored for Parkinson's disease. NIMH SBIR Phase I grant ($458,385) awarded 2023 for depression indication. In-vivo biomarker data using touchscreen Probabilistic Reward Task (PRT) model targeted Mar 2025.

Novel oral small molecule tau oligomerization inhibitor for Alzheimer's disease, Parkinson's disease, and other tauopathies. Disease-modifying approach targeting aggregation of tau proteins. Confirmed tau anti-aggregation properties in cell-based systems. Michael J. Fox Foundation grant funded (amount undisclosed). In-vivo proof-of-concept study results expected H2 2025.

Secondary sources list PSY-06 as a pending/preclinical MDD programme, but the current Psy Therapeutics site does not show a separate PSY-06 asset. Treat as a mapping-cleanup item until a company source confirms whether this remains active or has been folded into PSY-01/another MDD programme.